Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Drug interactions: from theory to practice].

A J Scheen1

  • 1Université de Liège, Belgique. andre.scheen@chu.ulg.ac.be

Revue Medicale De Liege
|August 17, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].

Revue medicale de Liege·2008
Same author

[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].

Revue medicale de Liege·2008
Same author

[Isolated tricuspid valve endocarditis as a cause of fever of unknown origin].

Revue medicale de Liege·2008
Same author

[A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge].

Revue medicale de Liege·2008
Same author

[Therapy of type 2 diabetes: between insulin sensitizers and insulin secreting agents].

Revue medicale de Liege·2008
Same author

[Aspirin resistance in diabetic patients: laboratory entity or clinical reality?].

Revue medicale de Liege·2007

Polypharmacy increases the risk of dangerous drug-drug interactions, often underestimated in clinical practice. Understanding interaction mechanisms, like those involving cytochrome P450, is crucial for patient safety.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Drug Safety

Context:

  • Increasingly complex pharmacotherapy necessitates ambitious therapeutic targets for care and prevention.
  • Polypharmacy is common, leading to a high risk of drug-drug interactions.
  • Drug-drug interactions are often underestimated despite causing serious adverse events.

Purpose:

  • To review medication use cautions and conditions favoring harmful drug interactions.
  • To analyze the mechanisms of drug interactions, focusing on cytochrome P450 and P-glycoprotein.
  • To provide clinical examples of frequent and dangerous drug interactions.

Summary:

  • This paper discusses the complexities of modern pharmacotherapy and the prevalence of polypharmacy.
  • It highlights the significant risks and underestimation of drug-drug interactions, which can lead to severe adverse events.

Related Experiment Videos

  • Mechanisms of interaction, particularly those involving the cytochrome P450 enzyme system and P-glycoprotein, are analyzed.

    • Impact:

    • Enhances understanding of drug-drug interaction risks in polypharmacy.
    • Provides clinicians with knowledge to mitigate potentially fatal adverse drug events.
    • Improves patient safety through better management of complex medication regimens.